Newfeed

MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: